Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.75 |
| ▸ | FAAH | O00519 | 5/20 | 0.56 |
| ▸ | PPARA | Q07869 | 4/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | TERT | O14746 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11003091 | 1.00 | EPHX2 (0.75) | EPHX2FAAHPPARATRPV1TERT | |
| SCHEMBL4092435 | 1.00 | EPHX2 (0.75) | EPHX2FAAHPPARATRPV1TERT | |
| SCHEMBL1962433 | 1.00 | EPHX2 (0.75) | EPHX2FAAHPPARATRPV1TERT | |
| SCHEMBL9777847 | 1.00 | EPHX2 (0.75) | EPHX2FAAHPPARATRPV1TERT | |
| SCHEMBL8349583 | 1.00 | EPHX2 (0.75) | EPHX2FAAHPPARATRPV1TERT | |
| SCHEMBL11370740 | 1.00 | EPHX2 (0.75) | EPHX2FAAHPPARATRPV1TERT | |
| SCHEMBL11370737 | 1.00 | EPHX2 (0.75) | EPHX2FAAHPPARATRPV1TERT | |
| SCHEMBL2219389 | 1.00 | EPHX2 (0.75) | EPHX2FAAHPPARATRPV1TERT | |
| SCHEMBL1962429 | 1.00 | EPHX2 (0.75) | EPHX2FAAHPPARATRPV1TERT | |
| SCHEMBL9777844 | 1.00 | EPHX2 (0.75) | EPHX2FAAHPPARATRPV1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117500819-A | Lipid and composition | 相互药工株式会社 | 2024-02-02 | — | — | CN | disclosed |
| WO-2022215758-A1 | LIPID AND COMPOSITION | 相互薬工株式会社 | 2022-10-13 | — | — | WO | disclosed |
| EP-3231790-B1 | METHOD FOR PRODUCING CATIONIC LIPID | NOF CORP (JP) | 2019-11-06 | — | — | EP | disclosed |
| CN-109983128-A | Oligonucleotide composition and its method | 波涛生命科学有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-107001238-B | The manufacturing method of cation lipid | 日油株式会社 | 2019-04-26 | — | — | CN | disclosed |
| CN-108137492-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-107879960-A | For transmitting the lipid and lipid composition of active component | 诺华股份有限公司 | 2018-04-06 | — | — | CN | disclosed |
| CN-105164102-B | Lipids and lipid compositions for delivery of active ingredients | 诺华股份有限公司 | 2017-12-15 | — | — | CN | disclosed |
| US-9834502-B2 | Method for producing cationic lipid | NOF CORPORATION (JP) | 2017-12-05 | — | — | US | disclosed |
| EP-3231790-A1 | METHOD FOR PRODUCING CATIONIC LIPID | NOF Corporation (JP) | 2017-10-18 | — | — | EP | disclosed |
| WO-1999033851-A1 | N-HET-SUBSTITUTED GLYCEROPHOSPHOETHANOLAMINES | CLARION PHARMACEUTICALS, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| EP-0523189-B1 | CATIONIC LIPIDS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | VICAL INC (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5730157-A | GLYCEROPHOSPHOETHANOLAMINES | CLARION PHARMACEUTICALS INC. (US) | 1998-03-24 | — | — | US | disclosed |
| US-5703062-A | ANTITUMOR AGENT; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | CLARION PHARMACEUTICALS INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5665714-A | N-substituted glycerophosphoethanolamines | CLARION PHARMACEUTICALS INC. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5459127-A | Drug delivery, extracellular treatment | VICAL, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| EP-0523189-A4 | — | VICAL INC (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5264618-A | For transport of biological active agents into cells for viral agents or polynucleotides or immunogenic peptides | VICAL, INC. (US) | 1993-11-23 | — | — | US | disclosed |
| EP-0523189-A1 | CATIONIC LIPIDS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | VICAL, INC. (US) | 1993-01-20 | — | — | EP | disclosed |
| WO-1991016024-A1 | CATIONIC LIPIDS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | VICAL, INC. (US) | 1991-10-31 | — | — | WO | disclosed |